Onco360 Oncology Pharmacy’s Post

Let PharPoint help with your next leukemia or lymphoma trial. We are driven by our passion for better treatment options for these patients. #LeukemiaClinicalResearch; #LymphomaClinicalResearch; #PharPoint; #PassionForResearch

🌍 September is Leukemia and Lymphoma Awareness Month! 🌍 According to the National Cancer Institute (NCI), 62,770 new cases of leukemia are expected in the United States in 2024. When it comes to lymphoma, 80,620 people in the U.S. are estimated to develop non-Hodgkin lymphoma, while 8,570 new cases of Hodgkin lymphoma are also expected this year. Join PrimeVigilance in spreading awareness this month. Together, we can make a difference and work towards improving outcomes for blood cancer patients around the world. #Pharmacovigilance #leukemia #lymphoma

TODAY at 2 pm EST! We explore the evolution of BTK inhibitors that are reshaping how we approach patient care for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Join us as Evan Slater, PharmD, from Rocky Mountain Cancer Centers, unpacks the essential pharmacokinetics and pharmacodynamics of this promising BTK inhibitor. Gain insights into the latest exploratory studies, innovative dosing strategies, and pricing dynamics crucial for optimizing patient outcomes. https://lnkd.in/eyeGJdGW 

BEIGENE AND CLL SOCIETY PARTNER TO ADVANCE TEST BEFORE TREAT™ CAMPAIGN BeiGene has recently announced its new partnership with CLL Society, the world’s leading authority for chronic lymphocytic leukemia and small lymphocytic lymphoma cancer patients. Together, they are advancing Test Before Treat, an awareness campaign that aims to connect with healthcare providers and educate patients with CLL/SLL about the critical importance of biomarker testing before initial treatment and retesting at each subsequent treatment to help ensure each patient receives the most effective, personalized therapy. READ MORE... https://lnkd.in/ekkmzGzA

Anti-CD7 Allogeneic CAR-T Cells👇 Phase 1/2 Dose-Escalation/Dose-Expansion Study of Anti-CD7 Allogeneic CAR-T Cells (WU-CART-007) in Relapsed or Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma (T-ALL/LBL) https://lnkd.in/gDzjR2qC

Blood cancers are more common than many people realize. In fact, last year leukemia, lymphoma and myeloma accounted for an estimated 9.4% of all new cancer cases in the U.S. At Amgen, we’re addressing the toughest forms of blood cancer, including acute lymphoblastic leukemia and multiple myeloma. 🔗Learn more at https://lnkd.in/gwYcDqeS #WorldBloodCancerDay

Fact: Over a million people every year around the world will experience the diagnosis of a blood cancer. During National Blood Cancer Awareness Month, increase your knowledge about Leukemia, Myeloma, and Lymphoma and their need for improved diagnosis, treatment, and research funding. To learn more about blood cancers and how to get involved, visit https://hubs.li/Q02NdScW0 on the National Today website. #BloodCancerAwarenessMonth #diagnostics #Leukemia #Myeloma #Lymphoma

On #WorldBloodCancerDay, we’re taking a moment to recognize the need for transformational treatments for people across the globe who are diagnosed with lymphoma, leukemia or myeloma each day. At ADC Therapeutics, we’re working with urgency to develop #antibodydrugconjugates in areas of high unmet need to bring hope to patients with #cancer, including hematologic cancers. #WBCD

Establishing rapport, building trust, and empowering patients with cancer are important outcomes of effective patient-provider communication. Learn more about key insights derived from ACCC and The Leukemia & Lymphoma Society focus groups in the most recent Oncology Issues: https://bit.ly/4ddUy5Q.

Cancer is not just a single disease: it has 100 types and affects different parts of the body 5 main types of cancer: ☑ Sarcomas ☑ Melanoma ☑ Lymphoma ☑ Carcinoma ☑ Leukemia Let’s raise awareness, support, and strive for a future to promote cancer is curable. #TheHealthcareInsights #Sarcomas #Melanoma #Lymphoma #Carcinoma #Leukemia